The American Cancer Society published a report assessing the progress made in its 25-year goal to reduce cancer death rates by 50 percent. The report finds areas where progress was substantial, and others where it was not.
Last week, Richard Pazdur was named to the position of director of FDA’s Center for Drug Evaluation and Research. Much has been written about how Pazdur, with nearly a three-decade long career at the agency, represents a stabilizing choice for FDA as it faces inner and outer turmoil.
